HOME >> MEDICINE >> NEWS
Avoiding wishful thinking over new drugs more trials should be double-blinded say cancer experts

Italian researchers have urged that doctors should, wherever possible, be blinded to which drug a patient is receiving in a trial when the endpoint involves subjective judgements by the investigators.

They believe it would lessen the risk of wishful thinking an unconscious tendency by doctors to expect new drugs to perform better than the older ones they are being tested against.

This perception of a drugs effectiveness was named wish bias', when it was first reported more than a decade ago. In a report published in the current issue of Annals of Oncology* the research team says it may help to explain why the response rate of tumours to a new drug decreased over time.

Dr Roldano Fossati and colleagues from the Mario Negri Institute in Milan combed through the results of 29 randomised trials that took place between 1975 and 1999. They analysed the response rate of 2,234 women with advanced breast cancer who had been in the arms of the trials using the anti-cancer drug, doxorubicin (Adriamycin). They extracted the global (i.e. complete plus partial) response rate from all the trials.

"We found that every five years there was a 11% relative decrease in the odds of a global response and most of this decrease was in the partial response rate, where evaluation involves more subjective judgement than is involved in determining complete response," said Dr Fossati.

Of the 29 studies they investigated, only one had used a double blind** approach, and in two studies patients records were just externally audited.

"In these situations a bias due to financial and academic conflicts of interest or more subtle forms of wish bias could easily arise and account for an impression that when a drug is new it does better," said Dr Fossati.

The team carried out the assessment of the 29 studies to test their hypothesis that doctors unconscious favourable attitudes to new treatments may result in a tendency to overestimate their
'"/>

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
44-1536-772181
European Society for Medical Oncology
12-Mar-2002


Page: 1 2

Related medicine news :

1. Chronic back pain shrinks thinking parts of the brain, study finds
2. Integration of agriculture, medicine requires new ways of thinking
3. Fit seniors better able to react when quick thinking needed, study says
4. Brain imaging technology can reveal what a person is thinking about
5. Research challenges conventional thinking on ways to treat prostate cancer
6. UW research shows risk factors for relapse among health care professionals who abuse drugs
7. New studies show mixed results on epilepsy drugs and birth defects
8. Newly discovered pathway might help in design of cancer drugs
9. Study examines consequences of Thailands war on drugs
10. Computational tool predicts how drugs work in cells, advancing efforts to design better medicines
11. Three anti-platelet drugs used in combination are safe

Post Your Comments:
(Date:8/28/2014)... 2014 In the healthcare industry, there ... struggle with: How can the overall quality of patient ... of the healthcare industry tackles this question, and has ... job satisfaction and the quality of patient care. ... in “ Organizational Factors related to Improving Quality of ...
(Date:8/28/2014)... August 28, 2014 Tea Leaves ... with Gigya, the leader in Connected Consumer Management. ... Leaves will have the opportunity to build more ... who they are and how they like to ... the world’s biggest brands to understand and connect ...
(Date:8/28/2014)... Livermore, CA (PRWEB) August 28, 2014 ... newest California physician, James Patel M.D. of Livermore, California. ... the best and most qualified physicians, and in accordance ... and our patients to Dr. Patel’s practice. , Initially ... at a young age, Dr. Patel was shaped by ...
(Date:8/28/2014)... 2014 The need for larger space has ... few years. The new location - 4700 Bryant Irvin Court, ... larger office space than TLC had in the past, as ... pleased about our new location because it represents a good ... be double in size compared to the current one, the ...
(Date:8/27/2014)... August 28, 2014 Author and orthopedic ... takes readers on the thrilling adventures of sharp and ... in 2012, is gearing up for a new marketing ... into two novellas , “Prescription: Murder” follows the ... finds himself dodging assassination attempts and thwarting criminals. In ...
Breaking Medicine News(10 mins):Health News:New Healthcare Study Explores Strategies for Improving Patient Care 2Health News:New Healthcare Study Explores Strategies for Improving Patient Care 3Health News:New Healthcare Study Explores Strategies for Improving Patient Care 4Health News:Tea Leaves Health Begins Important New Partnership with Gigya 2Health News:Tea Leaves Health Begins Important New Partnership with Gigya 3Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 2Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 3Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 4Health News:William H. Simon Launches New Marketing Campaign for Book 2
(Date:8/27/2014)... , Aug. 27, 2014 TWi ... final approval from the United States Food and ... Application (ANDA) for megestrol acetate 125mg/ml oral suspension, ... TWi is the first-to-file and under Hatch Waxman ... of marketing exclusivity.  TWi has completed the pre-launch ...
(Date:8/27/2014)... 2014 Reportbuyer.com has added a ... Terms & Agreements in Pharma, Biotech and ... The Co-development Terms and Agreements in ... understanding and unprecedented access to the co-development ... worlds leading life science companies. The ...
(Date:8/27/2014)... and MENLO PARK, Calif. , ... (OTCQB: DMPI), developer of advanced cancer therapeutics , ... 16th Annual Rodman & Renshaw Global Investment Conference, sponsored ... will take place Tuesday, September 9th at 2:55 p.m. ... the New York Palace Hotel in New ...
Breaking Medicine Technology:TWi Pharmaceuticals Receives US FDA Final Approval on Generic Megestrol Acetate 125mg/ml Oral Suspension 2Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 2Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 3Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 4Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 5Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 6Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 7DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 2DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 3DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 4
Cached News: